AET
This page has not been fully approved by the PsychonautWiki administrators. It may contain incorrect information, particularly with respect to dosage, duration, subjective effects, toxicity and other risks. It may also not meet PW style and grammar standards. |
Summary sheet: AET |
α-Ethyltryptamine (also known as a-ET, Monase) is a short-acting synthetic psychedelic that was first sold as a pharmaceutical antidepressant (Monase) in 1961. It was emergency scheduled (made illegal) on March 12, 1993 and has remained uncommon since. [1]
Pharmacology
This pharmacology section is incomplete. You can help by adding to it. |
α-Ethyltryptamine is structurally and pharmacologically related to aMT, α-methyltryptamine.
Subjective effects
Disclaimer: The effects listed below cite the Subjective Effect Index (SEI), an open research literature based on anecdotal user reports and the personal analyses of PsychonautWiki contributors. As a result, they should be viewed with a healthy degree of skepticism.
It is also worth noting that these effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects. Likewise, adverse effects become increasingly likely with higher doses and may include addiction, severe injury, or death ☠.
Physical effects
-
- Neurotoxicity - may produce serotonergic neurotoxicity[2][3][4]
- Perception of bodily lightness - At light to common doses feelings of body lightness have been reported with AET.
- Stimulation - AET is primarily stimulating and has been described as 'exciting.'
- Physical euphoria - Provides a physical pleasure reportedly more akin to Amphetamine than MDMA.
{{{2}}}
Legal status
This legality section is a stub. As such, it may contain incomplete or wrong information. You can help by expanding it. |
AET is Schedule 1 in the United States. This means it is illegal to manufacture, buy, possess, or distribute (sell, trade or give) without a DEA license. AET was emergency scheduled on March 12, 1993 and the permanently added to Schedule I on September 12, 1994
- ↑ AET, Erowid, 2022
- ↑ Glennon RA, Dukat MG (December 2023). "α-Ethyltryptamine: A Ratiocinatory Review of a Forgotten Antidepressant". ACS Pharmacology & Translational Science. 6 (12): 1780–1789. doi:10.1021/acsptsci.3c00139. PMC 10714429 Check
|pmc=
value (help). PMID 38093842. Unknown parameter|pmc-embargo-date=
ignored (help) - ↑ Oeri HE (May 2021). "Beyond ecstasy: Alternative entactogens to 3,4-methylenedioxymethamphetamine with potential applications in psychotherapy". Journal of Psychopharmacology. 35 (5): 512–536. doi:10.1177/0269881120920420. PMC 8155739 Check
|pmc=
value (help). PMID 32909493. - ↑ Huang XM, Johnson MP, Nichols DE (July 1991). "Reduction in brain serotonin markers by alpha-ethyltryptamine (Monase)". European Journal of Pharmacology. 200 (1): 187–190. doi:10.1016/0014-2999(91)90686-k. PMID 1722753.